ASCO 2017 - Locally advanced or metastatic solid tumors: GDC-0919+atezolizumab delivers promising phase 1b results

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Across all dose levels, only 1 DLT and no G 4/5 AEs in this phase 1b trial of the IDO1 inhibitor GDC-0919+the PD-L1 targeting atezolizumab (Tecentriq).

Why this matters

  • Combination generally well tolerated.
  • Demonstrated peripheral IDO1 modulation and preliminary efficacy d...